The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

Tirzepatide has been shown to help people lose more weight compared to semaglutide at the dosage regimens currently available ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Researchers report yet another positive finding for GLP-1s. The participants in this trial had lower BMIs than the participants in the many other trials that have shown the benefits of the GLP-1s.

Affordable and alternative versions of popular weigh loss drugs, like Ozempic and Wegovy, may no longer be available.

In STRIDE, published simultaneously in The Lancet, the functional benefit of injectable semaglutide was apparent as early as 26 weeks and was ... all-cause death (4% vs 8%, HR 0.46, 95% CI 0. ...

The trial has enrolled participants who are intended to be titrated on weekly semaglutide injections for 8 weeks (0.25 mg/week for 4 weeks followed by 0.5 mg/week for 4 weeks) before being ...

Over 4-week intervals ... bouts of nausea in studies was 8 days. However, most digestive side effects of semaglutide are mild to moderate and go away after dosing increases.

One of the questions we have to ask is how to prioritize; if you're in the clinic with a patient and they can't afford the 8 drugs that ... or specifically semaglutide, based on the results ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs ... Starting last week, some compounding pharmacies ...

They included 174,584 patients with diabetes who received semaglutide (mean age, 58.3 years; 51.8% women), propensity ... ranged from 1 month to 4 years after the index date.

In a study funded by Novo Nordisk, which manufactures Ozempic and Wegovy, people who stopped taking semaglutide after 68 weeks of use regained two-thirds of lost weight. How long do you stay on ...